The collaboration will focus initially on ligament and tendon repair products that will feature coatings based on BioSET’s proprietary F2A synthetic growth factor technology. The BioSET F2A peptide is a synthetic mimetic of the natural human FGF-2 growth factor that is known to play key role in the body’s healing and repair processes.
Doug Kohrs, president and CEO of Tornier, said: “Our collaboration with BioSET evidences Tornier’s long term commitment to innovative biologic and synthetic materials to improve clinical outcomes for both hard tissue and soft tissue orthopedic repair procedures.”